Skip to content
Screener

Immunic, Inc. IMUX Q3 2026 earnings

Reported November 13, 2026 · Before market open

EPS-$0.99Miss by $0.20
EPS estimate-$0.79
“As we approach the top-line data from our Phase 3 ENSURE trials in relapsing multiple sclerosis (MS) in December, we believe Immunic is entering one of the most important periods in its history. We are evolving from a science-driven biotechnology company into a fully integrated commercial organization, with a key focus on understanding and addressing the needs of people living with MS. We believe vidofludimus calcium has the potential to address mechanisms associated with both the neurodegenerative and inflammatory drivers of the disease, which, if confirmed in our Phase 3 trials, could offer a differentiated treatment option in MS. Subject to positive ENSURE results, we are preparing for a potential New Drug Application (NDA) submission in relapsing MS, while we continue to advance our Phase 3 program in progressive MS.”
Erik Lundgren

Next report

Date not yet announced

FAQ

When did Immunic, Inc. report Q3 2026 earnings?
Immunic, Inc. (IMUX) reported Q3 2026 earnings on November 13, 2026 before market open.
What were Immunic, Inc.'s Q3 2026 revenue and EPS?
Immunic, Inc. reported eps of $-0.99 for Q3 2026.
Did Immunic, Inc. beat estimates in Q3 2026?
EPS missed the consensus estimate of $-0.79 by $0.20.
How did Immunic, Inc.'s Q3 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps declined 661.5% from $-0.13.
Where can I find Immunic, Inc.'s Q3 2026 SEC filings?
You can read the 8-K earnings release (0001493152-26-051543) and the 10-Q periodic report (0001280776-26-000021) directly on SEC EDGAR. The filing index links above go to sec.gov.